Jabs designed to combat obesity might lower the likelihood of heart attacks, strokes, or heart failure among obese individuals, irrespective of the extent of weight loss experienced during the medication regimen. This indicates the potential for the treatment to yield benefits beyond mere reduction of excess body fat. Professor John Deanfield, who led the study, said the findings “have important clinical implications”. Report by Covellm. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Category
🗞
NewsTranscript
00:00 These drugs, the GLP-1 receptor agonists,
00:03 have shifted from being diabetes drugs to obesity drugs,
00:07 and now have the potential to modify important diseases
00:11 and add to our ability to treat heart disease
00:13 and other conditions as well.
00:15 So it is a landmark moment in the way we think
00:18 about GLP-1 receptor agonists and their role
00:21 in not only managing obesity,
00:24 but also managing patients' important conditions